Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma
Autor: | Ilse van Engen-van Grunsven, Gerald W. Verhaegh, Stefan M. Willems, Wim van Boxtel, Maike J. M. Uijen, Jack A. Schalken, Marianne A. Jonker, Carla M.L. van Herpen |
---|---|
Přispěvatelé: | Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS) |
Rok vydání: | 2020 |
Předmět: |
Oncology
Male Cancer Research HEPATOCYTE GROWTH-FACTOR Gene Expression Kaplan-Meier Estimate Proto-Oncogene Mas Salivary duct carcinoma Androgen chemistry.chemical_compound 0302 clinical medicine MEMBRANE ANTIGEN-EXPRESSION ADENOID CYSTIC CARCINOMA Receptors VASCULATURE Neoplasm Metastasis 030223 otorhinolaryngology Lymph node In Situ Hybridization Aged 80 and over OUTCOMES Tissue microarray Hazard ratio Middle Aged Proto-Oncogene Proteins c-met Cadherins Prognosis Salivary Gland Neoplasms Immunohistochemistry Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] Carcinoma Ductal medicine.anatomical_structure Receptors Androgen 030220 oncology & carcinogenesis SURVIVAL Female Disease Susceptibility Oral Surgery Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] Adult medicine.medical_specialty Proteasome Endopeptidase Complex C-Met BREAST 03 medical and health sciences All institutes and research themes of the Radboud University Medical Center Internal medicine Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] medicine PSMA Biomarkers Tumor Humans Survival analysis SCATTER FACTOR erbB-2 Aged Neoplasm Staging Proportional Hazards Models business.industry Proportional hazards model E-cadherin Genes erbB-2 medicine.disease chemistry Genes Salivary gland cancer HER-2 ANDROGEN DEPRIVATION THERAPY business |
Zdroj: | Oral Oncology, 110:105018. ELSEVIER SCIENCE BV Oral Oncology, 110 |
ISSN: | 1879-0593 1368-8375 |
Popis: | Objectives: Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancer. Androgen receptor (AR) (96%) and HER2 (29-46%) expression, and a high propensity for regional lymph node metastases are hallmarks of the disease. We hypothesized that c-MET, E-cadherin, PSMA tumor and PSMA neovascular expression may be prognostic factors in SDC.Materials and methods: Expression levels of these proteins were established on tissue microarrays containing 165 primary SDC tumor specimens. Association with survival was studied with Kaplan-Meier curves, and univariable and multivariable Cox regression models. Furthermore, association with lymph node status, AR and HER2 expression, and gender was studied.Results: We found that patients with high PSMA tumor expression showed a significantly longer overall survival (OS) (median 83 vs. 43 months, P = 0.022), a trend towards a longer DFS (median 51 vs. 22 months, P = 0.094), and significantly reduced hazard ratio for death in the univariable Cox regression model (HR 0.46, P = 0.034). In the multivariable model only a high number of tumor-positive lymph nodes and high age (> 80) at diagnosis were prognostic for poor OS. High PSMA tumor expression was also significantly associated with low N-stage (P = 0.001) and expression was higher in women versus men (P = 0.029). High PSMA tumor expression and Ecadherin loss were significantly associated with strong and weak AR-expression, respectively (P = 0.033 and P = 0.007). None of the factors were significantly associated with HER2 expression.Conclusion: c-MET, E-cadherin, and tumor and neovascular PSMA expression are no independent prognostic factors in SDC. |
Databáze: | OpenAIRE |
Externí odkaz: |